In a new brain-imaging study, UK researchers will explore how DMT impacts brain function, behaviour and well-being.
Awakn Life Sciences has announced that its Phase III clinical trial exploring the use of ketamine-assisted therapy for the treatment of severe alcohol use disorder (AUD)...
Small Pharma has received approval to carry out a first-in-human Phase 1 trial with its injectable deuterated DMT candidate – SPL028 – from the UK Medicines...
UK-based global nootropics company Puresport has had its Reishi, Cordyceps and Lion’s Mane supplements certified by Informed Sport, the gold-standard independent certification body.
Breaking Convention’s 11th conference, Worlds Collide, will feature themed panel discussions, art exhibitions and stalls.
Clerkenwell Health is expanding its pan-European advisory board with the addition of Dr David Erritzoe, Dr Dea Siggaard Stenbæk, Dr Kim Kuypers and Dr James Stone...
In recent weeks, much has been made of psychedelic drugs’ potential to redefine mental health treatment.
UK-startup Clerkenwell Health is opening Europe’s first ever facility to host commercial psychedelic clinical trials in London.
Leading UK psychedelics company Compass Pathways is entering into a pioneering collaboration with King’s College London and South London and Maudsley NHS Foundation Trust to accelerate...
On International Women’s Day, Psychedelic Health takes a look at just some of the women who are spearheading the psychedelic renaissance in the UK.
